阿司匹林治疗血管性痴呆的临床对照研究

目的研究痴呆患者的血清Fg、hs-CRP、IL-6水平与健康人的差异,探讨阿司匹林治疗血管性痴呆(VD)的临床疗效。方法将入选痴呆患者随机分为两组,治疗组20例,对照组20例。对照组给予控制血压及神经保护等常规治疗;治疗组患者在常规治疗基础上加服肠溶阿司匹林,1次/d,每次100mg,共服药3个月。治疗后以简易智力状态检查表(MMSE)得分作为疗效评定。在入组时抽取患者的血液进行Fg、hs-CRP、IL-6的检测,并与正常健康人40例的相比较。结果治疗组患者治疗12周后MMSE得分较对照组差异有统计学意义(P0.05),治疗12周后治疗组较对照组总体疗效比较差异有统计学意义(P0.01);痴呆患者的Fg、hs-CRP、IL-6水平明显高于正常对照组,且与正常对照组相比差异有统计学意义(P0.05)。结论阿司匹林能明显地改善血管性痴呆患者的智能减退,并且有良好的临床疗效,值得进行继续的研究。

Treatment of Vascular Dementia with Aspirin:A Clinical Control Study

Objective To study the difference in serum Fg, hs-CRP and IL-6 levels between vascular dementia patients and normal healthy people to explore the therapeutic effect of aspirin on vascular dementia. Methods The enrolled 40 patients were randomly divided into control group（n=20）and aspirin group（n=62）. All the patients were treated by using conventional therapy such as anti-hypertension and neuro-protection. The patients of the aspirin group were given aspirin 100mg once every day for 12 weeks in addition. All the patients were evaluated by MMES scale. We took the blood from the vascular dementia patients to detect Fg, hs-CRP and IL-6 and to compared them with normal healthy people. Results There was a significant difference in both the MMES score and the total therapeutic effect after 12-week treatment between the two groups （P〈0.05 or 0.01 ）.The Fg, hs-CRP and IL-6 levels in vascular dementia patients were obviously higher than those of the normal healthy people, with a significant difference （P〈0.05）. Conclusion Aspirin can distinctly improve intelligence decrease of vascular dementia patients, with a better therapeutic effect , and more studies should be needed.